238 related articles for article (PubMed ID: 15508059)
21. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
[TBL] [Abstract][Full Text] [Related]
22. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
[TBL] [Abstract][Full Text] [Related]
23. Granulomatous tracheo-bronchitis associated with Crohn's disease.
Xia K; Wolf J; Friedman S; Carr-Locke DL
MedGenMed; 2004 Feb; 6(1):18. PubMed ID: 15208530
[TBL] [Abstract][Full Text] [Related]
24. Crohn's disease of the esophagus: report of a case.
Ohta M; Konno H; Kamiya K; Suwa D; Baba M; Tanaka T; Nakamura T; Nishino N; Sugimura H; Nakamura S
Surg Today; 2000; 30(3):262-7. PubMed ID: 10752780
[TBL] [Abstract][Full Text] [Related]
25. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide.
Fedorak RN; Bistritz L
Adv Drug Deliv Rev; 2005 Jan; 57(2):303-16. PubMed ID: 15555744
[TBL] [Abstract][Full Text] [Related]
26. [Esophageal Crohn's disease].
Martínez Sempere JF; Aparicio Tormo JR; Moya García MI; Trigueros Mateos M; Casellas Valdé JA; Palazón Azorín JM
Gastroenterol Hepatol; 1997 Jan; 20(1):17-20. PubMed ID: 9072191
[TBL] [Abstract][Full Text] [Related]
27. [Methotrexate-induced pneumonitis in a woman with Crohn's disease].
Brechmann T; Heyer C; Schmiegel W
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1759-62. PubMed ID: 17713885
[TBL] [Abstract][Full Text] [Related]
28. Iatrogenic cushing syndrome secondary to a probable interaction between voriconazole and budesonide.
Jones W; Chastain CA; Wright PW
Pharmacotherapy; 2014 Jul; 34(7):e116-9. PubMed ID: 24757038
[TBL] [Abstract][Full Text] [Related]
29. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
[TBL] [Abstract][Full Text] [Related]
30. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies.
Plamondon S; Ng SC; Kamm MA
Aliment Pharmacol Ther; 2007 Mar; 25(5):557-67. PubMed ID: 17305756
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease.
Dilger K; Alberer M; Busch A; Enninger A; Behrens R; Koletzko S; Stern M; Beckmann C; Gleiter CH
Aliment Pharmacol Ther; 2006 Feb; 23(3):387-96. PubMed ID: 16422998
[TBL] [Abstract][Full Text] [Related]
32. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease.
Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB
Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392
[TBL] [Abstract][Full Text] [Related]
33. A successful switch from prednisone to budesonide for neuropsychiatric adverse effects in a patient with ileal Crohn's disease.
Nahon S; Pisanté L; Delas N
Am J Gastroenterol; 2001 Jun; 96(6):1953-4. PubMed ID: 11419871
[No Abstract] [Full Text] [Related]
34. [Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis].
Minnee RC; Stokkers P; Riemens SC; Hommes DW
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2290-5. PubMed ID: 16240855
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Crohn's disease with budesonide: this rose still has thorns!
Valentine JF
Am J Gastroenterol; 2002 Apr; 97(4):785-6. PubMed ID: 12003409
[No Abstract] [Full Text] [Related]
36. [Esophageal localizations of Crohn's disease].
Gaucher P; Bigard MA; Begue JY; Laugros A; Regent D; Macinot C
Nouv Presse Med; 1977 Apr; 6(16):1369-72. PubMed ID: 857244
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: Retrospective study.
Astegiano M; Pagano N; Sapone N; Simondi D; Bertolusso L; Bresso F; Demarchi B; Pellicano R; Bonardi R; Marconi S; Rizzetto M
Biomed Pharmacother; 2007 Jul; 61(6):370-6. PubMed ID: 17399941
[TBL] [Abstract][Full Text] [Related]
38. [New therapeutic modalities in Crohn's disease].
Rachmilewitz D
Harefuah; 1999 Jun; 136(12):943-5. PubMed ID: 10955155
[No Abstract] [Full Text] [Related]
39. Sulfasalazine-induced lupus syndrome in a patient with Crohn's disease.
Carr-Locke DL
Am J Gastroenterol; 1982 Sep; 77(9):614-6. PubMed ID: 6126117
[TBL] [Abstract][Full Text] [Related]
40. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?
Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA
Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
